
Biodesix (BDSX) Stock Forecast & Price Target
Biodesix (BDSX) Analyst Ratings
Bulls say
Biodesix Inc. demonstrates a strong financial outlook with a projected revenue growth of 30% for 2026, primarily driven by a 32% increase in lung diagnostic testing revenue and a 14% rise in development services and other revenue streams. The company’s forecast indicates an anticipated lung diagnostic testing revenue of $98 million, contingent upon successful execution of its sales force expansion strategy, which aims to increase its representatives to approximately 120 by the end of 2026. Additionally, Biodesix is noted for its sufficient capitalization and disciplined operational approach, positioning it well to achieve positive adjusted earnings in the near future.
Bears say
Biodesix Inc experienced a revenue miss in the first quarter of 2025, leading to a reduction in revenue guidance for the year, which was linked to a shift in the company's commercial strategy. This adjustment in strategy raises concerns about the company's ability to capitalize on existing market opportunities and generate consistent revenues moving forward. Given the reliance on diagnostic testing services and the potential challenges in their biopharmaceutical partnerships, the outlook appears increasingly negative for Biodesix's financial performance in the near term.
This aggregate rating is based on analysts' research of Biodesix and is not a guaranteed prediction by Public.com or investment advice.
Biodesix (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares